Precipio Ships First IV-Cell® Order to Major US Healthcare System
21. März 2023 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics...
Precipio Signs First IV-Cell Customer Agreement
10. Mai 2022 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that American Oncology Network (AON) of Fort Myers, Florida,...
Precipio & ADS Biotec Launch Seven Beta sites for IV-Cell™
06. Oktober 2020 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), along with its partner ADS Biotec announce the launch of the beta phase...
Precipio Signs Exclusive Manufacturing Agreement for IV-Cell™
04. Juni 2019 09:10 ET
|
Precipio, Inc.
NEW HAVEN, Conn., June 04, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has entered into an exclusive subcontracting manufacturing...